Why Sarepta Therapeutics Fell 14.7% This Week
Sarepta Therapeutics (NASDAQ: SRPT), a biotech company that specializes in genetic therapies for rare diseases, dropped 14.7% this week, according to data from S&P Global Market Intelligence. To start the week, the company announced results from its three phase 3 trials for SRP-9001 to treat Duchenne muscular dystrophy (DMD), which is caused by gene mutations that disrupt the dystrophin protein that is crucial for muscle functions. The trials, which measured the response of SRP-9001 on 120 juvenile patients, said that patients improved on the North Star Ambulatory Assessment (NSAA) scale compared with untreated patients.